Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock1 min readUpdated: Jul 24, 2024https://www.prnewswire.com/news-releases/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock-302203465.html?tc=eml_cleartime
https://www.prnewswire.com/news-releases/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock-302203465.html?tc=eml_cleartime
Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock
Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
Comments